The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $186.20

Today's change0.00 0.00%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $186.20

Today's change0.00 0.00%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc closed at (U.S.)$186.20.

Shares have lost 1.66% over the last five days, but have gained 19.36% over the last year to date. This security has underperformed the S&P 500 by 32.93% during the last year.

Key company metrics

  • Open(U.S.) $191.08
  • Previous close(U.S.) $186.20
  • High(U.S.) $194.00
  • Low(U.S.) $185.31
  • Bid / Ask-- / --
  • YTD % change+19.36%
  • Volume253,886
  • Average volume (10-day)397,035
  • Average volume (1-month)396,561
  • Average volume (3-month)350,711
  • 52-week range(U.S.) $128.50 to (U.S.) $314.88
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$7.08
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5,679.05%

Intercept Pharmaceuticals Inc has a net profit margin of -5,679.05%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.38%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue0100
Total other revenue--------
Total revenue0100
Gross profit--------
Total cost of revenue--------
Total operating expense49413637
Selling / general / administrative2113129
Research & development28282427
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-49-40-35-36
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-48-39-35-36
Income after tax-48-39-35-36
Income tax, total--------
Net income-48-39-35-36
Total adjustments to net income--------
Net income before extra. items-48-39-35-36
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-48-39-35-36
Inc. avail. to common incl. extra. items-48-39-35-36
Diluted net income-48-39-35-36
Dilution adjustment--------
Diluted weighted average shares24222121
Diluted EPS excluding extraordinary itemsvalue per share-1.99-1.78-1.63-1.69
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.99-1.78-1.63-1.69